TO THE ASSISTANT COMMISSIONER OF TRADEMARKS:

1. NAME OF CONVEYING PARTY(IES) (ASSIGNOR(S)): ASTA Medica GmbH

4.2.02

7. ADDITIONAL NAME(S) OF CONVEYING PARTY(IES) ATTACHED? YES NO

2. PARTY(IES) (ASSIGNEE(S)) RECEIVING INTEREST:

NAME: Zentaris AG

ADDRESS: Weismullerstraße 45, 60314 Frankfurt/Main, Germany

7. ADDITIONAL NAME(S) & ADDRESS(ES) ATTACHED? YES NO

3. NATURE OF CONVEYANCE (DOCUMENT):

(Submit herewith only one document for recordation—multiple copies of same Assignment signed by different inventors is one document)

ASSIGNMENT OF WHOLE PART INTEREST EXEC. DATE: March 19, 2002

ORIGINAL FACSIMILE/PHOTOCOPY

CHANGE OF NAME VERIFIED TRANSLATION

SECURITY MERGER OTHER

EXECUTION DATE(S) ON THE DECLARATION IF FILED HEREWITH: (NOTE: IF DATES ON DECLARATION AND ASSIGNMENT DIFFER SEE ATTY)

4.5 APPL. NO.(S) OR PAT NO.(S). OTHERS ON ADDITIONAL SHEET(S) attached? YES NO

5. Name & Address of Party to Whom Correspondence Concerning Document Should be Mailed:

Pillsbury Winthrop LLP
Intellectual Property Group
1100 Tysons Boulevard
McLean, VA 22102

6. NUMBER INVOLVED:

APPLNS 21 + PATS 0 = TOTAL = 21

7. AMOUNT OF FEE ENCLOSED: (Code 581) ABOVE TOTAL x $40 = $840

5. ATTY DKT:

P 0000326 PTZ/Nau/Goe

MATTER NO. CLIENT REF.

8. IF ABOVE FEE IS MISSING OR INADEQUATE CHARGE SUFFICIENCY OF DEPOSIT ACCOUNT NUMBER: 03-3975

UNDER ORDER NO 098501 0000326
dup. sheet not required CLIENT NO. MATTER NO.

9. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

[Signature]
Blair E. Taylor
Attorney
Date: April 2, 2002

10. Total number of pages including this cover sheet, attachments and document (do not file dup. Cover sheet)

FILE WITH PTO RETURN RECEIPT (PAT-103A)

Att Sec: BET/LMR TEL: (703) 905-2198 FAX: (703) 905-2500

PATENT

PAT-114X 10/01

REEL: 12745 FRAME: 0831
<table>
<thead>
<tr>
<th>Inventor(s)</th>
<th>Patent No.</th>
<th>Issue Date</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICKEL et al. (M# 243925)</td>
<td>6,093,704</td>
<td>July 25, 2000</td>
<td>USE OF DOPAMINE RECEPTOR ANTAGONISTS IN PALLIATIVE TUMOR THERAPY</td>
</tr>
<tr>
<td>ENGELE et al. (M# 238594)</td>
<td>6,054,432</td>
<td>April 25, 2000</td>
<td>MEANS FOR TREATING PROSTATE HYPERTROPHY AND PROSTATE CANCER</td>
</tr>
<tr>
<td>ENGELE et al. (M# 249124)</td>
<td>5,998,377</td>
<td>Dec. 7, 1999</td>
<td>MEANS FOR TREATING PROSTATE CANCER</td>
</tr>
<tr>
<td>ENGELE et al. (M# 249126)</td>
<td>6,071,882</td>
<td>June 6, 2000</td>
<td>MEANS FOR TREATING PROSTATE HYPERTROPHY AND PROSTATE CANCER</td>
</tr>
<tr>
<td>ENGELE et al. (M# 242395)</td>
<td>6,106,805</td>
<td>Aug. 22, 2000</td>
<td>DIAGNOSTIC COMPOSITION CONTAINING AN LH-RH ANTAGONIST FOR HYSTEROSCOPY</td>
</tr>
<tr>
<td>FERRUTI et al. (M# 235999)</td>
<td>5,916,998</td>
<td>June 29, 1999</td>
<td>COPOLYMERS WITH POLYESTER POLYCARBONATE BLOCKS...FOR THE PREPARATION OF...MATRICES</td>
</tr>
<tr>
<td>ENGELE et al. (M# 251132)</td>
<td>6,022,860</td>
<td>February 8, 2000</td>
<td>IMMobilized and activity-stabilized complexes of lhrh antagonists...preparation</td>
</tr>
<tr>
<td>ENGELE et al. (M# 244938)</td>
<td>6,054,555</td>
<td>April 25, 2000</td>
<td>process for the preparation of immobilized and...complexes of lhrh antagonists</td>
</tr>
<tr>
<td>McMAHON et al. (M# 259983)</td>
<td>6,093,728</td>
<td>July 25, 2000</td>
<td>METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE...COMPounds</td>
</tr>
<tr>
<td>ENGELE et al. (M# 221219)</td>
<td>5,985,834</td>
<td>Nov. 16, 1999</td>
<td>NOVA- AND DECAPEPTIDES IN THE PREPARATION...TREATMENT OF AIDS</td>
</tr>
<tr>
<td>ENGELE et al. (M# 223410)</td>
<td>5,773,032</td>
<td>June 30, 1998</td>
<td>LONG-ACTING INJECTION SUSPENSIONS AND A PROCESS FOR THEIR PREPARATION</td>
</tr>
<tr>
<td>KUTSCHER et al. (M# 254326)</td>
<td>5,942,493</td>
<td>Aug. 24, 1999</td>
<td>LH-RH ANTAGONISTS HAVING IMPROVED ACTION</td>
</tr>
<tr>
<td>NOSSNER et al. (M# 238389)</td>
<td>6,172,050</td>
<td>Jan. 9, 2001</td>
<td>PHOSPHOLIPID DERIVATIVES</td>
</tr>
<tr>
<td>McMAHON et al. (M# 259985)</td>
<td>6,180,631</td>
<td>Jan. 30, 2001</td>
<td>METHODS OF MODULATING SERINE/THREONINE...5-AZAQUIN-OXALINE-BASED COMPOUNDS</td>
</tr>
</tbody>
</table>
WHEREAS, ASTA Medica Gmbh
(whereafter ASSIGNOR) is the owner of the following United States Patent(s):

<table>
<thead>
<tr>
<th>Inventor(s)</th>
<th>Patent No.</th>
<th>Issue Date</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCHUMACHER et al. (M# 75923)</td>
<td>5,023,335</td>
<td>June 11, 1991</td>
<td>1,2-BIS (AMINOMETHYL) CYCLOBUTANE-PLATINUM COMPLEXES</td>
</tr>
<tr>
<td>SCHUMACHER et al. (M# 96080)</td>
<td>5,219,866</td>
<td>June 15, 1993</td>
<td>OCTADECYL-[2(3-METHYLPIPERIDINO)-ETHYL]-PHOSPHATE AND A PROCESS...</td>
</tr>
<tr>
<td>NOSSNER et al. (M# 201776)</td>
<td>5,449,798</td>
<td>Sept. 12, 1995</td>
<td>PHOSPHOLIPID DERIVATIVES CONTAINING HIGHER ELEMENTS OF THE FIFTH GROUP</td>
</tr>
<tr>
<td>NOSSNER et al. (M# 213975)</td>
<td>5,637,577</td>
<td>June 10, 1997</td>
<td>PHOSPHOLIPID DERIVATIVES CONTAINING HIGHER ELEMENTS OF THE FIFTH GROUP</td>
</tr>
<tr>
<td>NOSSNER et al. (M# 235295)</td>
<td>5,958,906</td>
<td>Sept. 28, 1999</td>
<td>PHOSPHOLIPID DERIVATIVES CONTAINING HIGHER ELEMENTS OF THE FIFTH...</td>
</tr>
<tr>
<td>ENGEL et al. (M# 217326)</td>
<td>6,319,192</td>
<td>Nov. 20, 2001</td>
<td>METHOD FOR THE TREATMENT OF FERTILITY DISORDERS</td>
</tr>
<tr>
<td>ENGEL et al. (M# 217326)</td>
<td>5,663,145</td>
<td>Sept. 2, 1997</td>
<td>PRODUCTS FOR ADMINISTERING AN INITIAL HIGH DOSE OF CETRORELIX...</td>
</tr>
</tbody>
</table>

(If there are additional patents, x box ☒ and continue list on an additional sheet the content of which is hereby incorporated by reference.)

ASSIGNOR does, for adequate consideration received from Zentaris AG (hereinafter ASSIGNEE) duly organized and existing under the laws of Germany and having its principal office at Weismullerstrasse 45, 60314 Frankfurt/Main, Germany acknowledge receipt of such consideration and hereby sells, assigns and transfers unto ASSIGNEE, its successors and assigns, the entire right, title and interest in, to and under each said Letters Patent, including, though not in way of limitation, all rights of recovery for past infringement thereof.

NOTE: The undersigned hereby authorizes Pillsbury Winthrop LLP of the above address to insert hereon any further identification necessary or desirable for recordation of this document.

EXECUTED this 19th day of March 2002

SEAL

ASTA Medica Gmbh
ASSIGNOR

By proxy
NAME: H.-J. Kromp
N. Leonhard

By proxy
TITLE: Head of Legal Department
Head of Tax Department

In the presence of:
Sig: 
SABINE SAUER , SABINE BARTH

Name:
SABINE SAUER , SABINE BARTH

RECROSSED: 04/02/2002
PATENT
REEL: 12745 FRAME: 0833